High Evidence
Research Overview
Retatrutide Research for Fatty Liver Disease
An evidence-based overview of research examining Retatrutide in the context of fatty liver disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Retatrutide reduced liver fat in a phase 2 MASLD substudy, with 81-82% relative reduction in liver fat at 24 weeks (8mg/12mg). Among treated patients, 79-86% achieved normalization of liver fat (below 5%), compared to 0% with placebo. The contribution of glucagon receptor activation versus weight loss and other pathways to these liver outcomes was not isolated.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.